[ad_1] ROCKVILLE, Md.and SUZHOU,China, Nov. 21, 2023 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of…
Tag: Innovent
Innovent Announces 2023 Interim Results and Business Updates
[ad_1] Remarkable achievements with accelerated growth and improved efficiency to underpin sustainable growth ROCKVILLE, M.D. and SUZHOU, China, Aug. 23, 2023 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a…
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the…
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the…
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 1, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment…
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
[ad_1] ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for…
Innovent Announces 2022 Annual Results and Business Updates
[ad_1] Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 28, 2023 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class…